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Abstract
Background: The outcome of patients with bacteraemia is influenced by the initial selection of
adequate antimicrobial therapy. The objective of our study was to clarify the influence of different
crude data correction methods on a) microbial spectrum and ranking of pathogens, and b)
cumulative antimicrobial susceptibility pattern of blood culture isolates obtained from patients
from intensive care units (ICUs) using a computer based tool, MONI.
Methods: Analysis of 13 ICUs over a period of 7 years yielded 1427 microorganisms from positive
results. Three different data correction methods were applied. Raw data method (RDM): Data
without further correction, including all positive blood culture results. Duplicate-free method
(DFM): Correction of raw data for consecutive patient's results yielding same microorganism with
similar antibiogram within a two-week period. Contaminant-free method (CFM): Bacteraemia
caused by possible contaminants was only assumed as true bloodstream infection, if an organism of
the same species was isolated from > 2 sets of blood cultures within 5 days.
Results: Our study demonstrates that different approaches towards raw data correction – none
(RDM), duplicate-free (DFM), and a contaminant-free method (CFM) – show different results in
analysis of positive blood cultures. Regarding the spectrum of microorganisms, RDM and DFM
yielded almost similar results in ranking of microorganisms, whereas using the CFM resulted in a
clinically and epidemiologically more plausible spectrum.
Conclusion:  For possible skin contaminants, the proportion of microorganisms in terms of
number of episodes is most influenced by the CFM, followed by the DFM. However, with exception
of fusidic acid for gram-positive organisms, none of the evaluated correction methods would have
changed advice for empiric therapy on the selected ICUs.
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Background
Nosocomial infections are estimated to affect 6–12% of
hospitalized patients [1]. Of these infections, bacteraemia
and fungaemia have the most significant effect on mortal-
ity. The outcome of patients with bacteraemia is influ-
enced by the initial selection of adequate antimicrobial
therapy [2]. Generally, selecting the antibiotic of choice
for the treatment of an infection is a multi-factorial proc-
ess, which includes site of infection, intrinsic activity of
the drug according to microbiological susceptibility test-
ing results, pharmacokinetics of the drug at the site of
infection, and potential side effects. However, before con-
sidering these factors, the choice of agent is mainly
dependant on knowledge of the organisms likely to be
involved. Contrarily, in clinical settings, microbiological
verification of an infection and susceptibility of the caus-
ative pathogen are usually not available at the time of clin-
ical diagnosis of an infection. In order not to endanger the
patient, a calculated (empirical) antimicrobial therapy
often has to be started without exact knowledge of the
causative pathogen and its antimicrobial susceptibility
profile. Furthermore,  very little changes occur in the anti-
microbial management even at the time when antimicro-
bial susceptibility results are available to physicians [3].
To assist physicians at an early stage with the empiric anti-
biotic choice for treating blood stream infections, a close
liaison with the clinical microbiologists is important. By
regularly monitoring and analyzing blood culture results
and by calculating the most frequently isolated microor-
ganisms together with their cumulative susceptibility pro-
files, the clinical microbiologist can narrow the plausible
cause of bacteraemia and susceptibility to antibiotics.
Therefore, analysis of occurrence of pathogens and their
cumulative susceptibility profiles is widely used in hospi-
tals, and recent attempts on how to standardize these
tasks were only developed within the last years [4]. How-
ever, applying these definitions manually on large data-
sets is time consuming, error-prone, and therefore, needs
development of expensive software tools.
For blood cultures, there are two concerns that demand
correction of crude data before generating statistics on the
frequency of occurrence of pathogens and their cumula-
tive antibiotic susceptibility profile. One refers to the fact
that in course of treatment and monitoring of the patient,
repetitive isolates are obtained, and it is generally believed
that by omission of these duplicates the final result will
not be biased by multiple cultures of one identical organ-
ism during a single infectious episode. The second consid-
eration is the difficulty of interpretation of
microbiological test results in distinguishing true episodes
of infection from possible contamination of specimens
[5]. In clinical practice, merging several other laboratory
results together with the clinical aspect of the affected
patient makes decision on this subject. Looking at micro-
biologic data alone often results in overestimation of the
real size of the situation, and this is especially true for
blood culture results. Several studies have found Staphylo-
coccus epidermidis to be the most common microorganism
isolated from blood cultures, accounting for 30–60% of
all episodes [6-9]. Although these findings were explained
partly by the increasing use of intravascular devices, which
can serve as portal of entry to the bloodstream, they may
be as well due to the retrospective nature of many studies
and the lack of criteria for differentiation between con-
taminated blood cultures and true bacteraemia. Two stud-
ies [5,10] could demonstrate that a simplified surveillance
definition for nosocomial bloodstream infections based
on microbiology data alone yielded comparable result to
the Centers for Diseases Control and Prevention's
(CDC's) definition for primary bloodstream infection
[11] for possible skin contaminant isolates with an agree-
ment rate of 75% [5] and 91% [10], respectively.
Based on these considerations, the objective of our study
was to clarify the influence of different crude data correc-
tion methods on a) microbial spectrum and ranking of
pathogens, and b) cumulative antimicrobial susceptibility
pattern of blood culture isolates obtained from patients
from intensive care units (ICUs).
Methods
The Vienna General Hospital is a 2,140 beds tertiary care
referral institution that serves as the teaching facility of the
Medical University of Vienna. The hospital cares for about
90,000 inpatients annually. Daily, more than 500 patient
samples are sent to the Division of Clinical Microbiology
for further processing. After analyzing samples, a clinical
microbiologist verifies the results, and findings are down-
loaded to the hospital's central laboratory database,
stored and then forwarded to the sample sender. Simulta-
neously, the results are downloaded to the MONI (Moni-
toring of Nosocomial Infections) database, which has a
relational, Oracle-based architecture located on a separate
server. MONI is a database and surveillance system
designed to monitor and detect nosocomial infections
[12-15]. Currently, the system offers three categories of
applications: a) administration tools, which enable to
control database settings and adjusting database parame-
ters; b) a database query tool (FlexScan), which allows to
extract records in accordance with manually selected
restrictions (for example sender, microorganism, sample,
antibiotic resistance profile), or to conduct automatic
queries based on knowledge-based rules, resulting in
stratified standard analysis of proportions of microorgan-
isms and cumulative antimicrobial susceptibility profiles;
c) an automatic surveillance tools using rules for monitor-
ing of alert organisms (e.g. methicillin-resistant Staphylo-
coccus aureus) and antibiotic resistance profiles (MONI/BMC Medical Informatics and Decision Making 2009, 9:27 http://www.biomedcentral.com/1472-6947/9/27
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ALERT), monitoring of cross infections (MONI/CROSS), and
monitoring of frequencies and trends (MONI/TREND). The
hospital's infection control team analyzes the intelligent
alarms generated by MONI, and reacts to them by initiat-
ing necessary countermeasures.
No ethical approval was needed for this study, as data
acquisition followed Austrian federal law on data safety,
and data pre-processing and analysing occurred anony-
mously.
Data acquisition and processing
Data acquisition was performed using the system's data-
base query tool FlexScan. Since preliminary reports of
blood culture results can introduce considerable redun-
dancy into a database of microbiology results, only the
final reports from each sample are downloaded to the
MONI database. For purpose of this study, three separate
queries were conducted, one using the programs duplicate
result filter (duplicate-free method – DFM), the other
without any data correction (raw data method – RDM).
For the purpose of evaluating a new data correction rule,
a third query was performed using definitions published
by Yokoe et al. [10] (contaminant-free method – CFM).
Following the selection of a time period (1 January 1998
– 31 December 2004), a sampling material (blood cul-
ture), and the wards under study (13 ICUs: 7 surgical, 5
medical, and 1 neuro-surgical), the program was started.
After performing the queries, results were stored in a
dynamic comma separated (*.csv) file, and analyzed for
more detail using a standard spreadsheet application (MS
Excel 2000, Microsoft Corporation, Redmond, Virginia).
Data from each patient included the following variables:
patient identification number, family name, first name,
date of birth, patient's age at sample collection, protocol
number of the blood culture report, date of sampling,
sender's department and ward, sampling material (blood
culture), identified organism, and antimicrobial suscepti-
bility pattern in terms of resistant, susceptible, or interme-
diate susceptible.
Definition of data correction rules
Raw data method (RDM)
Raw data were defined as data acquired by MONI without
any further correction. Hence, they included all positive
blood culture results obtained from patients of 13 ICUs
from 1 January 1998 – 31 December 2004 without any
further manipulation.
Duplicate-free method (DFM)
(figure 1) The duplicate-free method was defined as cor-
rection of raw data by elimination of duplicate results. A
duplicate result was defined as any result presenting the
same microorganism (genus and species) from the same
material (in this study blood culture) with a similar anti-
microbial susceptibility pattern (at least 85% similarity)
obtained from the same patient within a two-week period
starting from the last positive culture with the identical
organism. Intermediate susceptibility results were also
considered as resistant results. The accepted differences of
not more than 15% in antibiotic susceptibility was related
most to the clinical practice of testing additional antibiot-
ics or to omit re-testing of previously tested compounds.
Hence, in most cases the difference pertained more to
missing or additionally tested compounds. Only the first
result from a patient – representing one episode of bacter-
aemia – was enrolled for further analysis.
Contaminant-free method (CFM)
(figure 2) Considering the problem of contamination
with skin organisms, we applied the definitions published
earlier [10]. Possible skin contaminants were defined as
organisms, which are part of the normal skin flora, includ-
ing coagulase-negative staphylococci, Corynebacterium spe-
cies, alpha- or non-hemolytic streptococci [5], Bacillus
species, Propionibacterium acnes, micrococci, and Neisseria
species other than N. gonorrhoeae and N. meningitidis. All
coagulase-negative staphylococci were differentiated on
the species level, and not on the genus level alone. Other
bacteria and fungi were regarded as obligate pathogens
(e.g. Salmonella typhi, Staphylococcus aureus) and therefore
always considered as true cause of bacteraemia, whereby
only the first isolate within a 14-day period was counted
as one episode. Bacteraemia caused by a possible skin
contaminant organism was assumed as true if an organ-
ism of the same species with a similar antimicrobial sus-
ceptibility pattern (at least 85% similarity) was isolated
from two or more sets of blood cultures obtained from the
same patient within 5 days starting from the last positive
culture with the identical organism. In this case, this was
counted as a single episode of bacteraemia. If only one
isolate was recorded within this period, the blood culture
was regarded to be contaminated and was excluded from
further analysis.
Calculation and interpretation of antimicrobial 
susceptibility pattern
Because a gram stain is usually the first available informa-
tion which can be provided to a physician, susceptibility
results calculated by each method were summarized for
organisms grouped according to their gram stain result.
Based on empirical considerations, we excluded an anti-
microbial substance as possible choice for the calculated
antibiotic treatment of a bacteraemia, if its resistance
reached ≥ 10% against a given microorganism. For all iso-
lates, antimicrobial susceptibility testing was performed
by Kirby-Bauer disk-diffusion test according to the Clini-
cal and Laboratory Standards Institute (CLSI, before 2005
known as the National Committee for Clinical LaboratoryBMC Medical Informatics and Decision Making 2009, 9:27 http://www.biomedcentral.com/1472-6947/9/27
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Standards, NCCLS) guidelines [16], if appropriate. Results
of cumulative antimicrobial susceptibility were presented
as percentage of resistance against a tested antimicrobial
substance.
Statistical analysis
Differences of proportions between RDM, DFM and CFM
were calculated by applying the χ2 test, which gives the
probability that an observed difference between two
means or proportions is caused by chance. A P-value of
less than 0.05 was considered significant. Calculations
were performed using Epi Info 2000 v 1.1.2a (Centers for
Disease Control and Prevention, Atlanta, GA 30333,
USA).
Results
Microbial spectrum and ranking of microorganisms
Analysis from 13 ICUs (01/1998 – 12/2004) yielded 1427
microorganisms from positive blood culture results. The
spectrum of microorganisms, calculated by RDM, DFM,
and CFM, respectively, is shown in Table 1. By means of
all data correction methods, Staphylococcus epidermidis and
Staphylococcus aureus were the most common organisms.
However, regarding their proportion expressed as percent-
age of all episodes, there are significant differences. Table
2 and Table 3 show the difference of proportions obtained
by the different data correction methods as well as the
results of significance testing for possible skin contami-
nants and obligate pathogens, respectively. Although def-
initions for DFM and CFM did not differ for obligate
pathogens, due to the different size of denominators sta-
tistically significant differences with respect to proportion
of episodes could be observed. While there were differ-
ences in proportions for all microorganisms, no statisti-
cally significant difference was found for RDM vs. DFM.
Among the 333 microorganisms representing 23.3% of all
positive blood cultures summarized as "others" in Table
1, Staphylococcus spp. (other than S. epidermidis, S. aureus
and S. haemolyticus) (68; 4.8%), Corynebacterium spp. (39;
2.7%), Klebsiella spp. (32; 2.2%), viridans group strepto-
cocci (27; 1.9%), Candida spp. (other than C. albicans) (24;
1.7%),  Propionibacterium spp. (20; 1.4%), Streptococcus
pneumoniae (18; 1.3%), Citrobacter spp. (10; 0.7%), Entero-
Flowchart of the "if/then" rules of duplicate-free method (DFM) Figure 1
Flowchart of the "if/then" rules of duplicate-free method (DFM).
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bacter spp. (other than E. cloacae) (10; 0.7%), Serratia marc-
escens  (9; 0.6%), Acinetobacter spp. (other than A.
baumanii) (7; 0.5%), Stenotrophomonas maltophilia (7;
0.5%), Bacteroides spp. (6; 0.4%), Enterococcus spp. (other
than E. faecalis and E. faecium) (6; 0.4%), Ralstonia pickettii
(6; 0.4%), Burkholderia cepacia (4; 0.3%), Haemophilus spp.
(4; 0.3%), Peptostreptococcus anaerobius (4; 0.3%), Alcali-
genes xylosoxidans (3; 0.2%), Micrococcus spp. (3; 0.2%),
Morganella morganii (3; 0.2%), Proteus mirabilis (3; 0.2%),
Aerococcus viridans (2),  Clostridium spp. (2), Flavimonas
oryzihabitans  (2), group B streptococci (2), Actinomyces
meyeri (1), Bifidobacterium sp. (1), Campylobacter jejuni (1),
Cryptococcus neoformans (1), Gemella sp. (1), Kocuria sp. (1),
Lactobacillus casei (1), Listeria monocytogenes (1), Prevotella
denticola (1), Pseudomonas alcaligenes (1), group F (1), and
group G streptococci (1).
Results of antimicrobial susceptibility testing and appropriateness of 
antibiotics for empirical therapy
Figure 3 shows differences in the antimicrobial resistance
profile of gram-positive, Figure 4 of gram- negative organ-
isms. Considering an empirical cut-off level of ≥ 20% of
resistant organisms to an antibiotic as limit for appropri-
ateness of this agent for empirical therapy of infection
caused by gram-negative organisms, no data correction
method would have yielded a different recommendation
for empirical therapy. However, for gram-positive organ-
isms, only the application of the CFM changed signifi-
Flowchart of the "if/then" rules of contaminant-free method (CFM) Figure 2
Flowchart of the "if/then" rules of contaminant-free method (CFM).
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cantly the advice for empiric use of fusidic acid (RDM:
33%, DFM: 33%, and CFM: 19% resistance; P = 0.024).
Discussion
For small hospitals, a manually conducted review and
analysis of microbiological data is achievable, but limited
by the small numbers of isolates and therefore ensuing a
decreased reliability of results. At large institutions, there
is often an enormous pool of microbiological data, yield-
ing more accurate estimations on the prevalence of path-
ogens, but a manually conducted review is unattainable.
A large volume of clinical data demands the use of com-
puter systems, which analyze data in accordance with pro-
grammed "if/then" rules derived from models used by
medical experts. Naturally, direct transfer of human med-
ical decision-making behaviour to "if/then" rules for arti-
ficial intelligence-based computer programs is not always
possible, because most of the necessary information is not
easily available in electronic form (for example patient
temperature, abdominal discomfort, patient "looks" ill).
Also, because of the heterogeneity of used laboratory and
medical information systems even within the same hospi-
tal, merging of information obtained from different
sources is often futile. Therefore, the CFM, originally
designed as rapid method for surveillance of cases of
infection, is an interesting method, although its use
strongly depends on the availability of computer systems,
since complex "if/then" rules for data correction of large
datasets are highly time and concentration consuming
and consecutive human errors never can be ruled out.
However, because of the requirement of at least two sets
of positive blood cultures within 5 days, the prevalence of
true bacteraemia caused by possible skin contaminants
may be underestimated by the CFM if the practice of
obtaining only one set of blood cultures is common. This
situation usually does not arise at ICUs, since in this set-
ting often more than one set of blood culture is drawn on
consecutive days. The rationale for this practice is moni-
toring for success of therapy, and not to miss additional
infections by multiple resistant pathogens during antimi-
crobial therapy.
On the other hand, the CFM enables to study those micro-
organisms classified as "true" pathogens, and hence being
clinically and epidemiologically more relevant. Also, this
method gives better estimation of the proportion of the
organism isolated from blood cultures. Our study showed
Table 1: Comparison of the spectrum and ranking of microorganisms identified from blood cultures in 13 ICUs (1998–2004), analyzed 
by different data pre-processing methods.
RDMa DFMb CFMc
Rank Microorganism n % Rank Microorganism n % Rank Microorganism n %
1 Staphylococcus epidermidis 448 31.4% 1 Staphylococcus epidermidis 305 32.1% 1 Staphylococcus aureus 123 20.6%
2 Staphylococcus aureus 198 13.9% 2 Staphylococcus aureus 123 12.9% 2 Staphylococcus epidermidis 80 13.4%
3 Candida albicans 96 6.7% 3 Pseudomonas aeruginosa 58 6.1% 3 Pseudomonas aeruginosa 58 9.7%
4 Pseudomonas aeruginosa 89 6.2% 4 Candida albicans 56 5.9% 4 Candida albicans 56 9.4%
5 Escherichia coli 71 5.0% 5 Escherichia coli 41 4.3% 5 Escherichia coli 41 6.9%
6 Enterobacter cloacae 63 4.4% 6 Enterobacter cloacae 36 3.8% 6 Enterobacter cloacae 36 6.0%
7 Enterococcus faecalis 45 3.2% 7 Enterococcus faecalis 29 3.0% 7 Enterococcus faecalis 29 4.8%
8 Enterococcus faecium 34 2.4% 8 Enterococcus faecium 27 2.8% 8 Enterococcus faecium 27 4.5%
9 Acinetobacter baumannii 26 1.8% 9 Klebsiella pneumoniae 16 1.7% 9 Klebsiella pneumoniae 16 2.7%
10 Staphylococcus 
haemolyticus
24 1.7% 10 Staphylococcus 
haemolyticus
15 1.6% 10 Acinetobacter baumannii 13 2.2%
others 333 23.3% Others 245 25.8% others 119 19.9%
Total 1427 100.0 Total 951 100.0 total 598 100.0
a RDM = raw data method; b DFM = duplicate-free method; c CFM = contaminant-free method.
Table 2: Difference of proportions according to applied data correction method for possible skin contaminants.
RDM vs. DFM RDM vs. CFM DFM vs. CFM
% difference χ2 p-value % difference χ2 p-value % difference χ2 p-value
S. epidermidis 0.7% 0.12 0.728 18.0% 70.96 < 0.0001* 18.7% 68.69 < 0.001*
S. haemolyticus 0.1% 0.04 0.844 0.6% 1.33 0.249 0.7% 0.90 0.342
Corynebacterium spp. 0.2% 0.14 0.705 1.1% 2.26 0.132 1.3% 2.93 0.087
χ2 = Chi-square test; A p-value less than 0.05 (*) is considered to indicate a statistically significant difference.BMC Medical Informatics and Decision Making 2009, 9:27 http://www.biomedcentral.com/1472-6947/9/27
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Table 3: Difference of proportions according to applied data correction method for obligate pathogens.
RDM vs. DFM RDM vs. CFM DFM vs. CFM
% difference χ2 p-value % difference χ2 p-value % difference χ2 p-value
S. aureus 1.0% 0.43 0.510 6.7% 14.15 0.0002* 7.7% 16.02 < 0.001*
C. albicans 0.8% 0.67 0.413 2.7% 4.22 0.039* 3.5% 6.61 0.010*
P. aeruginosa 0.1% 0.02 0.881 3.5% 7.50 0.006* 3.6% 6.93 0.008*
χ2 = Chi-square test; A p-value less than 0.05 (*) is considered to indicate a statistically significant difference.
a percentage of 13.4% of Staphylococcus epidermidis using
CFM, which is a very plausible estimation on the real pro-
portion of infections caused by this organism according to
previous results of prospective studies on catheter-related
infections at ICUs [17]. Regarding susceptibility pattern
and implications on empiric antibiotic therapy, the CFM
showed only a difference to DFM or RDM for fusidic acid.
With regard to the associations of empiric therapy and
antimicrobial susceptibilities, the difference for the CFM
method for fusidic acid, while an interesting observation,
is not relevant to the topic of the study question.
Conclusion
Our study demonstrates that different approaches
towards raw data correction – none (RDM), duplicate-free
(DFM), and a contaminant-free method (CFM) – show
different results in analysis of positive blood cultures.
Regarding the spectrum of microorganisms, RDM and
DFM yielded almost similar results in ranking of microor-
Cumulative antimicrobial resistance profile of gram positive organisms Figure 3
Cumulative antimicrobial resistance profile of gram positive organisms. PEN = penicillin; OXA = oxacillin; ERY = 
erythromycin; CLI = clindamycin; GEN = gentamicin; AMK = amikacin; FOF = fosfomycin; FUS = fusidic acid; TMP = trimetho-
prim; RIF = rifampicin; CIP = ciprofloxacin; MOX = moxifloxaciln; TEC = teicoplanin; VAN = vancomycin.
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ganisms, whereas using the CFM resulted in a clinically
and epidemiologically more plausible spectrum. For pos-
sible skin contaminants, the proportion of microorgan-
isms in terms of number of episodes is most influenced by
the CFM, followed by the DFM. However, with exception
of fusidic acid for gram-positive organisms, none of the
evaluated correction methods would have changed advice
for empiric therapy on the selected ICUs.
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